Mohammed S Qayyum, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Mohammed S Qayyum MD Inc · 4 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Hazel Hawkins Memorial Hospital · Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Qayyum’s office at (408) 610-2001 to ask if they take your plan before you enroll.
California Medical Board record
Licence A56213 · Current
Licensed to practise in California · since 1996 · expires 2028-07-31 · University of London, Charing Cross and Westminster Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$1,102,659
Medicare paid this office $1,102,659 for 407 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 237 | $378,666 | $1,558 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 237 | $197,602 | $407 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 142 | $143,788 | $904 |
| Insertion of heart rhythm monitor under skin | 20 | $97,010 | $4,620 |
| Long return visit (40+ min) | 243 | $72,805 | $160 |
See all 28 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 237 | $378,666 | $1,558 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 237 | $197,602 | $407 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 142 | $143,788 | $904 |
| Insertion of heart rhythm monitor under skin | 20 | $97,010 | $4,620 |
| Long return visit (40+ min) | 243 | $72,805 | $160 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 268 | $50,574 | $185 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 60 | $49,320 | $107 |
| Return visit (30+ min) | 142 | $23,027 | $115 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 238 | $17,840 | $73 |
| Injection of drug or substance into vein | 238 | $9,477 | $39 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 140 | $9,352 | $60 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 17 | $6,351 | $61 |
| Injection, regadenoson, 0.1 mg | 236 | $4,399 | None |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 19 | $4,391 | $231 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 142 | $3,578 | $23 |
| Evaluation of cardiac rhythm monitor system | 31 | $2,770 | $49 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 41 | $2,638 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 29 | $1,913 | $24 |
| Programming of dual lead pacemaker system | 16 | $1,668 | $79 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 16 | $1,567 | $78 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $1,189 | $31 |
| Infusion, normal saline solution, 250 cc | 238 | $1,007 | None |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 13 | $935 | $62 |
| Electrocardiogram (ecg) 2-day continuous | 33 | $629 | $17 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 33 | $522 | $14 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $377 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 20 | $337 | $14 |
| Ultrasonic guidance for blood vessel access | 24 | $298 | $12 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 1-10 | None |
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
407 Original Medicare patients in 2024. Average age 78 · Women 45% · Also on Medicaid 3% · Health risk score 1.34. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 75% · Heart failure 41% · Diabetes 38% · Atrial fibrillation 31% · Chronic kidney disease 30% · Cancer 18% · COPD 16% · Depression 11% · Stroke 11% · Dementia 8%.
The office billed $2,952,959, Medicare allowed $1,407,227 and paid $1,102,659; for 6,828 services of 62 kinds; $5,501 of it was for drugs given in the office and $1,097,158 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 407 | 6,828 | 78 | 1.34 | $2,952,959 | $1,102,659 |
| 2023 | 414 | 7,723 | 78 | 1.42 | $2,653,697 | $998,191 |
| 2022 | 418 | 11,239 | 78 | 1.47 | $2,305,825 | $881,098 |
| 2021 | 400 | 11,003 | 78 | 1.47 | $2,385,082 | $916,806 |
| 2020 | 377 | 10,330 | 78 | 1.56 | $2,140,484 | $749,035 |
| 2019 | 392 | 11,971 | 77 | 1.53 | $1,868,343 | $661,253 |
| 2018 | 387 | 10,981 | 78 | 1.53 | $1,706,033 | $550,200 |
| 2017 | 417 | 12,661 | 77 | 1.67 | $1,829,364 | $518,039 |
| 2016 | 414 | 10,087 | 78 | 1.95 | $1,652,314 | $478,885 |
| 2015 | 381 | 7,536 | 77 | 1.82 | $1,089,511 | $385,381 |
| 2014 | 389 | 9,642 | 76 | 1.72 | $879,995 | $347,277 |
| 2013 | 389 | 2,535 | 77 | 1.75 | $808,830 | $310,107 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 31 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 170 | $266,717 | $1,551 |
| Insertion of heart rhythm monitor under skin | 32 | $155,298 | $4,853 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 170 | $139,565 | $406 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 137 | $137,075 | $932 |
| Long return visit (40+ min) | 241 | $75,512 | $160 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 245 | $47,338 | $189 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 74 | $36,169 | $78 |
| Injection, regadenoson, 0.1 mg | 132 | $22,582 | None |
| Return visit (30+ min) | 140 | $21,716 | $113 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 173 | $12,399 | $71 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 144 | $10,222 | $65 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 56 | $8,050 | $23 |
| Injection of drug or substance into vein | 172 | $6,839 | $39 |
| New patient visit (60+ min) | 26 | $3,932 | $151 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 137 | $3,390 | $23 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 16 | $3,330 | $208 |
| Evaluation of cardiac rhythm monitor system | 39 | $3,013 | $52 |
| Programming of dual lead pacemaker system | 24 | $2,759 | $81 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 20 | $2,703 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 36 | $2,134 | $25 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 25 | $1,522 | $61 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $1,454 | $27 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 14 | $1,351 | $79 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $1,064 | $33 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 42 | $765 | None |
| Infusion, normal saline solution, 250 cc | 172 | $707 | None |
| Electrocardiogram (ecg) 2-day continuous | 37 | $691 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 38 | $595 | $14 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 37 | $581 | $16 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 33 | $418 | $11 |
| Ultrasonic guidance for blood vessel access | 20 | $268 | $12 |
2022: 30 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 168 | $269,963 | $1,570 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 168 | $141,295 | $411 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 129 | $137,692 | $984 |
| Long return visit (40+ min) | 249 | $80,537 | $161 |
| Insertion of heart rhythm monitor under skin | 12 | $61,880 | $5,157 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 238 | $46,458 | $187 |
| Return visit (30+ min) | 135 | $19,430 | $109 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 171 | $12,531 | $72 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 48 | $10,149 | $25 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 131 | $10,025 | $69 |
| Injection, regadenoson, 0.1 mg | 48 | $9,314 | None |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 40 | $7,137 | $23 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 26 | $5,698 | $219 |
| Injection of drug or substance into vein | 112 | $4,710 | $42 |
| New patient visit (60+ min) | 26 | $4,503 | $173 |
| Programming of dual lead pacemaker system | 24 | $3,423 | $83 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 129 | $3,291 | $24 |
| Evaluation of cardiac rhythm monitor system | 32 | $3,004 | $54 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 44 | $2,782 | $60 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 22 | $2,203 | $82 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 122 | $2,199 | None |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 18 | $1,368 | $65 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 18 | $1,188 | $26 |
| Infusion, normal saline solution, 250 cc | 170 | $728 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 45 | $675 | $14 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 50 | $647 | $11 |
| Injection, aminophyllin, up to 250 mg | 86 | $603 | None |
| Ultrasonic guidance for blood vessel access | 34 | $428 | $12 |
| Electrocardiogram (ecg) 2-day continuous | 14 | $277 | $18 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 14 | $222 | $15 |
2021: 33 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 177 | $290,347 | $1,622 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 177 | $148,510 | $415 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 138 | $113,698 | $773 |
| Insertion of heart rhythm monitor under skin | 14 | $80,174 | $5,727 |
| Long return visit (40+ min) | 241 | $78,044 | $161 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 247 | $51,677 | $203 |
| Return visit (30+ min) | 181 | $32,711 | $116 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 184 | $13,260 | $71 |
| Injection, regadenoson, 0.1 mg | 64 | $12,609 | None |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 42 | $9,204 | $25 |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 11 | $7,443 | $573 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 13 | $6,635 | $510 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 33 | $6,549 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 72 | $5,739 | $79 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 17 | $4,136 | $243 |
| Programming of dual lead pacemaker system | 27 | $3,640 | $81 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 138 | $3,463 | $24 |
| Evaluation of cardiac rhythm monitor system | 28 | $2,714 | $50 |
| New patient visit (60+ min) | 13 | $2,602 | $200 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 25 | $2,583 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,563 | $183 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 119 | $2,520 | None |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 11 | $2,054 | $24 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 23 | $1,858 | $66 |
| Injection, aminophyllin, up to 250 mg | 174 | $1,230 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 18 | $1,160 | $28 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 17 | $1,110 | $65 |
| Infusion, normal saline solution, 250 cc | 184 | $820 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 52 | $706 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 34 | $603 | $15 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $453 | $23 |
| Ultrasonic guidance for blood vessel access | 33 | $441 | $12 |
| Heart rhythm recording of continous external ekg over 8-15 days | 22 | $326 | $15 |
2020: 31 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 163 | $263,642 | $1,551 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 163 | $133,188 | $392 |
| Insertion of heart rhythm monitor under skin | 15 | $79,979 | $5,332 |
| Long return visit (40+ min) | 293 | $71,788 | $120 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 218 | $43,731 | $188 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 42 | $31,154 | $742 |
| Return visit (30+ min) | 159 | $22,440 | $92 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 173 | $12,147 | $67 |
| Injection, regadenoson, 0.1 mg | 57 | $10,937 | None |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 14 | $8,278 | $552 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 33 | $7,575 | $230 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $5,418 | $493 |
| New patient visit (60+ min) | 30 | $5,001 | $167 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 28 | $3,495 | $24 |
| Programming of dual lead pacemaker system | 29 | $2,993 | $68 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 32 | $2,963 | $80 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 111 | $2,725 | None |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 21 | $2,560 | $24 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,461 | $176 |
| Evaluation of cardiac rhythm monitor system | 20 | $1,489 | $41 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 20 | $1,286 | $64 |
| Injection, aminophyllin, up to 250 mg | 167 | $1,155 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 42 | $997 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 50 | $936 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 13 | $906 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 66 | $861 | $11 |
| Infusion, normal saline solution, 250 cc | 172 | $717 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 12 | $669 | $27 |
| Ultrasonic guidance for blood vessel access | 44 | $599 | $12 |
| External ekg recording for more than 48 hours up to 21 days | 16 | $374 | $23 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 16 | $327 | $20 |
2019: 26 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 151 | $240,215 | $1,530 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 151 | $128,415 | $409 |
| Long return visit (40+ min) | 336 | $85,221 | $127 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 197 | $40,245 | $201 |
| Return visit (30+ min) | 235 | $35,719 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 167 | $11,940 | $69 |
| Injection, regadenoson, 0.1 mg | 49 | $9,221 | None |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 14 | $8,538 | $569 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 16 | $7,774 | $486 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 28 | $6,856 | $236 |
| New patient visit (60+ min) | 39 | $6,254 | $160 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $5,585 | $508 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 109 | $4,280 | None |
| Programming of dual lead pacemaker system | 34 | $3,573 | $63 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 33 | $3,247 | $83 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 16 | $3,044 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,174 | $181 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 98 | $1,670 | $16 |
| Injection, aminophyllin, up to 250 mg | 156 | $1,044 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 69 | $920 | $11 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 13 | $863 | $66 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 12 | $814 | $68 |
| Ultrasonic guidance for blood vessel access | 48 | $669 | $13 |
| Infusion, normal saline solution, 250 cc | 167 | $654 | None |
| External ekg recording for more than 48 hours up to 21 days | 16 | $499 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 16 | $436 | $24 |
2018: 24 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 125 | $196,569 | $1,536 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 125 | $97,131 | $379 |
| Long return visit (40+ min) | 335 | $84,910 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 192 | $39,355 | $199 |
| Return visit (30+ min) | 221 | $32,014 | $89 |
| New patient visit (60+ min) | 67 | $11,742 | $175 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 141 | $9,680 | $67 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 17 | $8,277 | $487 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 37 | $7,836 | $212 |
| Injection, regadenoson, 0.1 mg | 38 | $6,916 | None |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $5,387 | $490 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 95 | $4,113 | None |
| Programming of dual lead pacemaker system | 36 | $3,154 | $53 |
| Insertion of tube into chest or arm artery, initial third order branch | 14 | $3,150 | $210 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 15 | $2,777 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,941 | $176 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 111 | $1,899 | $16 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 23 | $1,842 | $80 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 13 | $1,515 | $49 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 15 | $970 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 69 | $792 | $11 |
| Ultrasonic guidance for blood vessel access | 57 | $747 | $12 |
| Injection, aminophyllin, up to 250 mg | 127 | $629 | None |
| Infusion, normal saline solution, 250 cc | 142 | $535 | None |
2017: 28 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 116 | $170,152 | $1,467 |
| Long return visit (40+ min) | 266 | $64,740 | $127 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 115 | $51,601 | $224 |
| Return visit (30+ min) | 287 | $51,428 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 200 | $43,752 | $210 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $25,284 | $486 |
| New patient visit (60+ min) | 72 | $12,791 | $178 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 139 | $9,706 | $69 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 40 | $8,730 | $218 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 42 | $7,657 | $92 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 123 | $3,856 | None |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 12 | $3,638 | $303 |
| Programming of dual lead pacemaker system | 37 | $3,459 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,341 | $176 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 164 | $3,257 | $16 |
| Critical care, first 30-74 minutes | 11 | $2,856 | $190 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 46 | $2,634 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,262 | $63 |
| Injection, regadenoson, 0.1 mg | 13 | $2,256 | None |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 24 | $2,004 | $80 |
| New patient visit (45+ min) | 15 | $1,781 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,723 | $91 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 11 | $1,267 | $60 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 71 | $824 | $11 |
| Injection of drug or substance into vein | 14 | $804 | $57 |
| Ultrasonic guidance for blood vessel access | 61 | $796 | $12 |
| Injection, aminophyllin, up to 250 mg | 126 | $747 | None |
| Infusion, normal saline solution, 250 cc | 166 | $470 | None |
2016: 28 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 70 | $101,742 | $1,433 |
| Return visit (30+ min) | 315 | $76,064 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 73 | $37,380 | $485 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 164 | $36,198 | $212 |
| Long return visit (40+ min) | 180 | $31,997 | $128 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 66 | $29,745 | $222 |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 27 | $15,829 | $546 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 71 | $13,070 | $93 |
| Critical care, first 30-74 minutes | 23 | $12,717 | $187 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 53 | $11,709 | $221 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $8,829 | $173 |
| New patient visit (60+ min) | 47 | $8,362 | $178 |
| New patient visit (45+ min) | 44 | $6,167 | $140 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $6,067 | $117 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 87 | $5,463 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $4,446 | $62 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 88 | $3,515 | None |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 38 | $3,253 | $79 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 55 | $3,082 | $55 |
| Programming of dual lead pacemaker system | 35 | $2,977 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 151 | $2,865 | $16 |
| Injection, regadenoson, 0.1 mg | 15 | $2,535 | None |
| Ultrasonic guidance for blood vessel access | 94 | $1,499 | $12 |
| Injection of drug or substance into vein | 20 | $1,117 | $56 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 14 | $949 | $63 |
| Hospital discharge day management, 30 minutes or less | 13 | $884 | $63 |
| Injection, aminophyllin, up to 250 mg | 96 | $651 | None |
| Infusion, normal saline solution, 250 cc | 135 | $337 | None |
2015: 33 services
| Return visit (30+ min) | 287 | $78,640 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 97 | $48,364 | $474 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $31,356 | $189 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 91 | $24,445 | $129 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 16 | $21,719 | $1,357 |
| Long return visit (40+ min) | 102 | $17,637 | $129 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 80 | $16,741 | $197 |
| Critical care, first 30-74 minutes | 27 | $13,743 | $191 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 23 | $11,928 | $459 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 77 | $11,196 | $118 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 17 | $8,783 | $488 |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 14 | $8,466 | $529 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 17 | $6,935 | $204 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 95 | $6,373 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $6,371 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,346 | $167 |
| Balloon dilation of single coronary artery or branch | 20 | $5,882 | $294 |
| New patient visit (45+ min) | 33 | $4,846 | $147 |
| New patient visit (60+ min) | 22 | $4,040 | $184 |
| Short return visit (20+ min) | 40 | $3,924 | $65 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 41 | $3,631 | $81 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 64 | $3,196 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 44 | $2,459 | $55 |
| Programming of dual lead pacemaker system | 28 | $2,449 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 97 | $2,081 | $16 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,438 | $63 |
| Ultrasonic guidance for blood vessel access | 87 | $1,298 | $12 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 14 | $1,230 | $65 |
| Injection, regadenoson, 0.1 mg | 12 | $1,130 | None |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 11 | $829 | $59 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 13 | $495 | $35 |
| Injection, aminophyllin, up to 250 mg | 64 | $333 | None |
| Infusion, normal saline solution, 250 cc | 105 | $35 | None |
2014: 24 services
| Return visit (30+ min) | 280 | $76,104 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 110 | $56,369 | $494 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $36,268 | $216 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 110 | $29,942 | $131 |
| Long return visit (40+ min) | 105 | $17,379 | $126 |
| New patient visit (60+ min) | 92 | $16,521 | $180 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 25 | $15,564 | $458 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 112 | $15,547 | None |
| Critical care, first 30-74 minutes | 23 | $9,969 | $195 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 42 | $8,321 | $194 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $8,064 | $175 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 106 | $7,079 | $64 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 65 | $3,891 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,715 | $64 |
| Short return visit (20+ min) | 27 | $2,337 | $63 |
| Programming of dual lead pacemaker system | 30 | $2,239 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 82 | $1,677 | $16 |
| Critical care, each additional 30 minutes | 15 | $1,662 | $98 |
| Emergency department visit with moderate level of medical decision making | 11 | $1,091 | $99 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 13 | $1,034 | $80 |
| Ultrasonic guidance for blood vessel access | 63 | $987 | $13 |
| Injection, aminophyllin, up to 250 mg | 111 | $225 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 13 | $121 | $8 |
| Infusion, normal saline solution, 250 cc | 111 | $30 | None |
2013: 23 services
| Return visit (30+ min) | 224 | $49,620 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 83 | $43,719 | $514 |
| Long return visit (40+ min) | 157 | $30,464 | $118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 126 | $23,229 | $175 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 82 | $22,244 | $132 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 28 | $17,011 | $473 |
| Critical care, first 30-74 minutes | 25 | $16,042 | $191 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 83 | $14,543 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $13,620 | $175 |
| New patient visit (60+ min) | 60 | $11,064 | $184 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 41 | $7,760 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 53 | $7,498 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 111 | $6,354 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 85 | $5,793 | $67 |
| Programming of dual lead pacemaker system | 34 | $2,308 | $50 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 21 | $2,163 | $77 |
| Short return visit (20+ min) | 16 | $1,160 | $68 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,137 | $95 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 42 | $852 | $18 |
| Ultrasonic guidance for blood vessel access | 32 | $480 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $212 | $19 |
| Injection, aminophyllin, up to 250 mg | 82 | $64 | None |
| Infusion, normal saline solution, 250 cc | 83 | $19 | None |
Drugs they prescribed that Part D paid
$668,985
Pharmacies billed $668,985 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,885) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,287 generic and 598 brand-name prescriptions · $668,985 in drug cost · 20 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xarelto | 135 | $193,563 | $1,434 |
| Repatha Sureclick | 215 | $168,982 | $786 |
| Eliquis | 79 | $91,545 | $1,159 |
| Entresto | 73 | $87,609 | $1,200 |
| Praluent | 30 | $29,497 | $983 |
See all 37 drugs
| Xarelto | 135 | $193,563 | $1,434 |
| Repatha Sureclick | 215 | $168,982 | $786 |
| Eliquis | 79 | $91,545 | $1,159 |
| Entresto | 73 | $87,609 | $1,200 |
| Praluent | 30 | $29,497 | $983 |
| Farxiga | 23 | $26,612 | $1,157 |
| Rosuvastatin | 408 | $7,508 | $18 |
| Metoprolol | 317 | $4,465 | $14 |
| Ezetimibe | 138 | $3,500 | $25 |
| Carvedilol | 171 | $1,493 | $9 |
| Flecainide Acetate | 39 | $1,478 | $38 |
| Sotalol | 56 | $1,467 | $26 |
| Losartan | 165 | $1,414 | $9 |
| Nebivolol | 15 | $1,367 | $91 |
| Atorvastatin | 94 | $1,240 | $13 |
| Amlodipine Besylate | 215 | $1,236 | $6 |
| Eplerenone | 21 | $1,002 | $48 |
| Pantoprazole | 64 | $969 | $15 |
| Diltiazem 24hr Er (Cd) | 13 | $873 | $67 |
| Isosorbide Mononitrate Er | 44 | $853 | $19 |
| Propafenone | 14 | $806 | $58 |
| Amiodarone | 26 | $711 | $27 |
| Clopidogrel | 33 | $601 | $18 |
| Verapamil Er | 14 | $597 | $43 |
| Digoxin | 20 | $567 | $28 |
| Spironolactone | 53 | $425 | $8 |
| Nitroglycerin | 24 | $377 | $16 |
| Omeprazole | 20 | $370 | $18 |
| Olmesartan Medoxomil | 13 | $256 | $20 |
| Furosemide | 33 | $253 | $8 |
| Allopurinol | 11 | $161 | $15 |
| Metoprolol | 22 | $157 | $7 |
| Pravastatin | 21 | $132 | $6 |
| Lisinopril | 36 | $125 | $3 |
| Hydrochlorothiazide | 17 | $109 | $6 |
| Famotidine | 12 | $36 | $3 |
| Amoxicillin | 11 | $17 | $2 |
Year by year
| 2024 | 2,885 | 307 | 0% (0) | 21% | $668,985 |
| 2023 | 2,873 | 284 | 0% (0) | 22% | $745,688 |
| 2022 | 2,642 | 265 | 0% (0) | 24% | $702,781 |
| 2021 | 2,700 | 261 | 0% (0) | 25% | $639,260 |
| 2020 | 2,817 | 251 | 0% (0) | None | $563,659 |
| 2019 | 2,654 | 262 | 0% (0) | 25% | $480,981 |
| 2018 | 2,442 | 247 | 0% (0) | 27% | $576,143 |
| 2017 | 2,189 | 231 | 0% (0) | 31% | $333,268 |
| 2016 | 1,910 | 223 | None | 34% | $242,684 |
| 2015 | 1,706 | 197 | None | None | $176,432 |
| 2014 | 1,464 | 160 | None | None | $116,773 |
| 2013 | 1,103 | 118 | None | None | $88,769 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Xarelto | 183 | $241,909 | $1,322 |
| Repatha Sureclick | 183 | $149,652 | $818 |
| Entresto | 66 | $88,842 | $1,346 |
| Eliquis | 78 | $71,414 | $916 |
| Praluent | 41 | $57,260 | $1,397 |
| Farxiga | 18 | $27,687 | $1,538 |
| Savaysa | 20 | $13,608 | $680 |
| Icosapent Ethyl | 26 | $13,296 | $511 |
| Rosuvastatin | 365 | $10,769 | $30 |
| Metoprolol | 306 | $4,784 | $16 |
| Ezetimibe | 91 | $3,624 | $40 |
| Flecainide Acetate | 46 | $3,133 | $68 |
| Carvedilol | 186 | $2,504 | $13 |
| Amlodipine Besylate | 209 | $2,458 | $12 |
| Ranolazine Er | 13 | $2,267 | $174 |
| Pantoprazole | 83 | $2,160 | $26 |
| Losartan | 142 | $2,155 | $15 |
| Sotalol | 64 | $1,894 | $30 |
| Diltiazem 24hr Er (Cd) | 20 | $1,480 | $74 |
| Atorvastatin | 93 | $1,410 | $15 |
| Amiodarone | 32 | $1,205 | $38 |
| Verapamil Er | 22 | $1,009 | $46 |
| Clopidogrel | 54 | $870 | $16 |
| Digoxin | 30 | $849 | $28 |
| Isosorbide Mononitrate Er | 33 | $803 | $24 |
| Olmesartan Medoxomil | 14 | $735 | $52 |
| Omeprazole | 24 | $658 | $27 |
| Spironolactone | 47 | $479 | $10 |
| Furosemide | 42 | $392 | $9 |
| Nitroglycerin | 15 | $335 | $22 |
| Metoprolol | 29 | $174 | $6 |
| Lisinopril | 35 | $168 | $5 |
| Pravastatin | 25 | $158 | $6 |
| Hydrochlorothiazide | 18 | $140 | $8 |
| Amoxicillin | 11 | $13 | $1 |
2022: 36 drugs
| Xarelto | 208 | $258,858 | $1,245 |
| Repatha Sureclick | 163 | $119,953 | $736 |
| Entresto | 81 | $103,175 | $1,274 |
| Praluent | 54 | $54,560 | $1,010 |
| Savaysa | 59 | $34,809 | $590 |
| Eliquis | 16 | $17,682 | $1,105 |
| Rosuvastatin | 311 | $13,023 | $42 |
| Icosapent Ethyl | 21 | $12,514 | $596 |
| Ezetimibe | 66 | $5,858 | $89 |
| Metoprolol | 269 | $5,180 | $19 |
| Ranolazine Er | 24 | $4,119 | $172 |
| Flecainide Acetate | 40 | $2,914 | $73 |
| Carvedilol | 166 | $2,485 | $15 |
| Olmesartan Medoxomil | 13 | $2,337 | $180 |
| Losartan | 129 | $2,059 | $16 |
| Eplerenone | 20 | $1,985 | $99 |
| Amlodipine Besylate | 175 | $1,979 | $11 |
| Pantoprazole | 63 | $1,711 | $27 |
| Atorvastatin | 101 | $1,634 | $16 |
| Sotalol | 60 | $1,496 | $25 |
| Amiodarone | 31 | $1,462 | $47 |
| Diltiazem 24hr Er (Cd) | 25 | $1,370 | $55 |
| Digoxin | 29 | $1,228 | $42 |
| Clopidogrel | 50 | $1,173 | $23 |
| Isosorbide Mononitrate Er | 42 | $1,062 | $25 |
| Metoprolol | 22 | $633 | $29 |
| Omeprazole | 19 | $594 | $31 |
| Chlorthalidone | 13 | $551 | $42 |
| Nitroglycerin | 13 | $542 | $42 |
| Furosemide | 54 | $320 | $6 |
| Torsemide | 13 | $320 | $25 |
| Spironolactone | 29 | $307 | $11 |
| Potassium Chloride | 11 | $288 | $26 |
| Pravastatin | 18 | $236 | $13 |
| Lisinopril | 24 | $210 | $9 |
| Hydrochlorothiazide | 13 | $102 | $8 |
2021: 39 drugs
| Xarelto | 210 | $239,154 | $1,139 |
| Entresto | 79 | $95,729 | $1,212 |
| Repatha Sureclick | 163 | $94,819 | $582 |
| Savaysa | 74 | $48,989 | $662 |
| Praluent | 67 | $39,239 | $586 |
| Vascepa | 24 | $20,852 | $869 |
| Rosuvastatin | 301 | $10,774 | $36 |
| Pradaxa | 13 | $10,558 | $812 |
| Metoprolol | 287 | $6,336 | $22 |
| Bystolic | 12 | $5,464 | $455 |
| Ezetimibe | 56 | $5,214 | $93 |
| Flecainide Acetate | 60 | $5,037 | $84 |
| Prasugrel | 33 | $4,574 | $139 |
| Ranolazine Er | 27 | $3,900 | $144 |
| Carvedilol | 180 | $2,846 | $16 |
| Losartan | 140 | $2,594 | $19 |
| Amiodarone | 36 | $2,416 | $67 |
| Eplerenone | 11 | $2,043 | $186 |
| Olmesartan Medoxomil | 13 | $1,994 | $153 |
| Atorvastatin | 109 | $1,764 | $16 |
| Diltiazem 24hr Er (Cd) | 24 | $1,639 | $68 |
| Nifedipine Er | 16 | $1,472 | $92 |
| Digoxin | 34 | $1,425 | $42 |
| Amlodipine Besylate | 101 | $1,407 | $14 |
| Pantoprazole | 42 | $1,261 | $30 |
| Sotalol | 56 | $1,156 | $21 |
| Isosorbide Mononitrate Er | 40 | $789 | $20 |
| Clopidogrel | 40 | $757 | $19 |
| Chlorthalidone | 12 | $593 | $49 |
| Metoprolol | 31 | $476 | $15 |
| Omeprazole | 21 | $457 | $22 |
| Nitroglycerin | 20 | $422 | $21 |
| Furosemide | 62 | $394 | $6 |
| Hydrochlorothiazide | 26 | $306 | $12 |
| Pravastatin | 21 | $295 | $14 |
| Lisinopril | 20 | $274 | $14 |
| Spironolactone | 27 | $251 | $9 |
| Ramipril | 12 | $177 | $15 |
| Amoxicillin | 21 | $21 | $1 |
2020: 41 drugs
| Xarelto | 187 | $203,845 | $1,090 |
| Entresto | 90 | $84,299 | $937 |
| Savaysa | 105 | $60,937 | $580 |
| Repatha Sureclick | 118 | $58,364 | $495 |
| Praluent | 43 | $25,039 | $582 |
| Vascepa | 30 | $19,622 | $654 |
| Rosuvastatin | 274 | $14,800 | $54 |
| Bystolic | 20 | $8,250 | $412 |
| Metoprolol | 315 | $7,904 | $25 |
| Prasugrel | 46 | $7,436 | $162 |
| Ezetimibe | 68 | $7,391 | $109 |
| Flecainide Acetate | 76 | $7,383 | $97 |
| Pradaxa | 11 | $5,302 | $482 |
| Ranolazine Er | 26 | $3,862 | $149 |
| Atorvastatin | 144 | $2,799 | $19 |
| Amiodarone | 48 | $2,716 | $57 |
| Carvedilol | 209 | $2,705 | $13 |
| Diltiazem 24hr Er (Cd) | 32 | $2,461 | $77 |
| Nifedipine Er | 21 | $2,028 | $97 |
| Nitroglycerin | 20 | $1,943 | $97 |
| Losartan | 128 | $1,922 | $15 |
| Olmesartan Medoxomil | 13 | $1,766 | $136 |
| Amlodipine Besylate | 114 | $1,260 | $11 |
| Digoxin | 28 | $1,126 | $40 |
| Clopidogrel | 35 | $937 | $27 |
| Clonidine | 15 | $903 | $60 |
| Sotalol | 38 | $864 | $23 |
| Furosemide | 94 | $642 | $7 |
| Pravastatin | 30 | $581 | $19 |
| Metoprolol | 39 | $533 | $14 |
| Isosorbide Mononitrate Er | 35 | $521 | $15 |
| Chlorthalidone | 13 | $441 | $34 |
| Pantoprazole | 25 | $358 | $14 |
| Hydrochlorothiazide | 36 | $327 | $9 |
| Lisinopril | 34 | $321 | $9 |
| Diltiazem | 13 | $313 | $24 |
| Omeprazole | 19 | $292 | $15 |
| Ramipril | 15 | $272 | $18 |
| Spironolactone | 27 | $195 | $7 |
| Calcitriol | 11 | $182 | $17 |
| Amoxicillin | 14 | $18 | $1 |
2019: 41 drugs
| Xarelto | 133 | $129,475 | $973 |
| Praluent | 65 | $57,404 | $883 |
| Savaysa | 121 | $57,219 | $473 |
| Entresto | 80 | $57,030 | $713 |
| Repatha Sureclick | 60 | $37,797 | $630 |
| Rosuvastatin | 217 | $15,369 | $71 |
| Ranexa | 25 | $12,606 | $504 |
| Metoprolol | 309 | $9,712 | $31 |
| Eliquis | 12 | $9,530 | $794 |
| Bystolic | 21 | $8,952 | $426 |
| Ranolazine Er | 20 | $5,767 | $288 |
| Prasugrel | 42 | $5,540 | $132 |
| Flecainide Acetate | 49 | $3,803 | $78 |
| Ezetimibe | 38 | $3,603 | $95 |
| Atorvastatin | 141 | $3,461 | $25 |
| Carvedilol | 222 | $3,169 | $14 |
| Diltiazem 24hr Er (Cd) | 16 | $3,052 | $191 |
| Amiodarone | 43 | $2,285 | $53 |
| Nifedipine Er | 17 | $1,455 | $86 |
| Clonidine | 23 | $1,316 | $57 |
| Sotalol | 38 | $1,276 | $34 |
| Amlodipine Besylate | 118 | $1,268 | $11 |
| Digoxin | 23 | $1,211 | $53 |
| Losartan | 99 | $1,199 | $12 |
| Isosorbide Mononitrate Er | 47 | $975 | $21 |
| Nitroglycerin | 19 | $951 | $50 |
| Bumetanide | 11 | $912 | $83 |
| Clopidogrel | 40 | $899 | $22 |
| Furosemide | 109 | $860 | $8 |
| Chlorthalidone | 17 | $756 | $44 |
| Spironolactone | 52 | $656 | $13 |
| Metoprolol | 48 | $508 | $11 |
| Hydrochlorothiazide | 38 | $469 | $12 |
| Lisinopril | 50 | $414 | $8 |
| Pravastatin | 30 | $368 | $12 |
| Potassium Chloride | 12 | $329 | $27 |
| Ramipril | 11 | $210 | $19 |
| Omeprazole | 14 | $167 | $12 |
| Benazepril | 17 | $150 | $9 |
| Pantoprazole | 17 | $150 | $9 |
| Amoxicillin | 17 | $46 | $3 |
2018: 38 drugs
| Opsumit | 11 | $104,962 | $9,542 |
| Praluent | 82 | $93,670 | $1,142 |
| Xarelto | 112 | $90,077 | $804 |
| Savaysa | 132 | $61,293 | $464 |
| Adcirca | 11 | $43,943 | $3,995 |
| Entresto | 71 | $40,743 | $574 |
| Ranexa | 64 | $29,658 | $463 |
| Repatha Sureclick | 15 | $13,854 | $924 |
| Prasugrel | 43 | $12,517 | $291 |
| Rosuvastatin | 154 | $9,771 | $63 |
| Metoprolol | 271 | $8,476 | $31 |
| Bystolic | 21 | $7,447 | $355 |
| Eliquis | 11 | $7,436 | $676 |
| Atorvastatin | 176 | $3,495 | $20 |
| Ezetimibe | 23 | $3,094 | $135 |
| Diltiazem 12hr Er | 12 | $2,788 | $232 |
| Carvedilol | 185 | $2,183 | $12 |
| Amiodarone | 42 | $1,943 | $46 |
| Flecainide Acetate | 28 | $1,754 | $63 |
| Clopidogrel | 59 | $1,178 | $20 |
| Digoxin | 11 | $977 | $89 |
| Isosorbide Mononitrate Er | 48 | $968 | $20 |
| Amlodipine Besylate | 100 | $965 | $10 |
| Sotalol | 44 | $914 | $21 |
| Pravastatin | 33 | $898 | $27 |
| Losartan | 77 | $873 | $11 |
| Furosemide | 107 | $815 | $8 |
| Spironolactone | 49 | $653 | $13 |
| Potassium Chloride | 25 | $544 | $22 |
| Nitroglycerin | 17 | $413 | $24 |
| Lisinopril | 59 | $374 | $6 |
| Hydrochlorothiazide | 39 | $364 | $9 |
| Metoprolol | 30 | $313 | $10 |
| Pantoprazole | 17 | $283 | $17 |
| Omeprazole | 12 | $245 | $20 |
| Propafenone | 12 | $239 | $20 |
| Benazepril | 14 | $117 | $8 |
| Amoxicillin | 21 | $78 | $4 |
2017: 42 drugs
| Savaysa | 140 | $57,449 | $410 |
| Xarelto | 74 | $52,523 | $710 |
| Effient | 52 | $46,806 | $900 |
| Praluent | 33 | $37,926 | $1,149 |
| Ranexa | 46 | $21,191 | $461 |
| Bystolic | 59 | $14,549 | $247 |
| Prasugrel | 17 | $9,086 | $534 |
| Rosuvastatin | 102 | $8,909 | $87 |
| Entresto | 14 | $7,782 | $556 |
| Zetia | 14 | $5,136 | $367 |
| Metoprolol | 174 | $4,933 | $28 |
| Diltiazem 12hr Er | 15 | $3,381 | $225 |
| Atorvastatin | 207 | $3,165 | $15 |
| Amiodarone | 30 | $2,415 | $80 |
| Digoxin | 18 | $1,326 | $74 |
| Carvedilol | 149 | $1,325 | $9 |
| Sotalol | 51 | $1,207 | $24 |
| Clopidogrel | 66 | $1,113 | $17 |
| Nitroglycerin | 21 | $1,079 | $51 |
| Clonidine | 13 | $1,028 | $79 |
| Pravastatin | 44 | $1,025 | $23 |
| Furosemide | 115 | $953 | $8 |
| Losartan | 82 | $776 | $9 |
| Flecainide Acetate | 13 | $716 | $55 |
| Amlodipine Besylate | 72 | $658 | $9 |
| Spironolactone | 45 | $604 | $13 |
| Diltiazem 24hr Er | 19 | $602 | $32 |
| Isosorbide Mononitrate Er | 33 | $589 | $18 |
| Potassium Chloride | 17 | $394 | $23 |
| Lisinopril | 74 | $325 | $4 |
| Metoprolol | 43 | $322 | $7 |
| Propafenone | 14 | $275 | $20 |
| Pantoprazole | 23 | $271 | $12 |
| Cartia Xt | 12 | $265 | $22 |
| Valsartan | 17 | $245 | $14 |
| Simvastatin | 14 | $242 | $17 |
| Enalapril Maleate | 12 | $140 | $12 |
| Hydrochlorothiazide | 32 | $139 | $4 |
| Benazepril | 16 | $110 | $7 |
| Amoxicillin | 13 | $65 | $5 |
| Atenolol | 12 | $58 | $5 |
| Clonidine | 12 | $41 | $3 |
2016: 40 drugs
| Effient | 87 | $67,799 | $779 |
| Savaysa | 112 | $42,992 | $384 |
| Ranexa | 39 | $20,772 | $533 |
| Xarelto | 28 | $20,308 | $725 |
| Crestor | 32 | $19,181 | $599 |
| Bystolic | 62 | $14,602 | $236 |
| Eliquis | 18 | $9,224 | $512 |
| Metoprolol | 138 | $4,964 | $36 |
| Zetia | 16 | $4,410 | $276 |
| Atorvastatin | 152 | $3,084 | $20 |
| Rosuvastatin | 20 | $2,049 | $102 |
| Potassium Chloride | 27 | $1,708 | $63 |
| Clopidogrel | 62 | $1,325 | $21 |
| Digoxin | 26 | $1,301 | $50 |
| Carvedilol | 107 | $1,110 | $10 |
| Diltiazem 24hr Er | 22 | $989 | $45 |
| Amiodarone | 39 | $965 | $25 |
| Sotalol | 47 | $935 | $20 |
| Pravastatin | 39 | $904 | $23 |
| Furosemide | 117 | $868 | $7 |
| Losartan | 76 | $809 | $11 |
| Isosorbide Mononitrate Er | 33 | $750 | $23 |
| Flecainide Acetate | 20 | $646 | $32 |
| Valsartan | 27 | $565 | $21 |
| Lisinopril | 71 | $536 | $8 |
| Amlodipine Besylate | 69 | $512 | $7 |
| Bumetanide | 12 | $467 | $39 |
| Spironolactone | 34 | $430 | $13 |
| Metoprolol | 47 | $331 | $7 |
| Warfarin | 19 | $326 | $17 |
| Pantoprazole | 35 | $318 | $9 |
| Simvastatin | 25 | $302 | $12 |
| Digox | 11 | $285 | $26 |
| Enalapril Maleate | 11 | $269 | $24 |
| Propafenone | 13 | $269 | $21 |
| Hydrochlorothiazide | 35 | $268 | $8 |
| Nitrostat | 11 | $258 | $23 |
| Fenofibrate | 11 | $175 | $16 |
| Benazepril | 12 | $84 | $7 |
| Amoxicillin | 15 | $65 | $4 |
2015: 37 drugs
| Effient | 86 | $50,277 | $585 |
| Xarelto | 36 | $19,657 | $546 |
| Crestor | 33 | $15,759 | $478 |
| Savaysa | 35 | $15,682 | $448 |
| Pradaxa | 16 | $9,551 | $597 |
| Bystolic | 45 | $8,633 | $192 |
| Ranexa | 19 | $8,187 | $431 |
| Metoprolol | 126 | $5,013 | $40 |
| Zetia | 11 | $3,463 | $315 |
| Atorvastatin | 91 | $2,009 | $22 |
| Pravastatin | 67 | $1,989 | $30 |
| Potassium Chloride | 41 | $1,521 | $37 |
| Carvedilol | 89 | $1,140 | $13 |
| Losartan | 101 | $1,137 | $11 |
| Digoxin | 27 | $1,037 | $38 |
| Furosemide | 132 | $976 | $7 |
| Clopidogrel | 72 | $971 | $13 |
| Isosorbide Mononitrate Er | 48 | $932 | $19 |
| Warfarin | 37 | $737 | $20 |
| Diltiazem 24hr Er | 13 | $713 | $55 |
| Pantoprazole | 46 | $637 | $14 |
| Flecainide Acetate | 21 | $633 | $30 |
| Hydralazine | 20 | $511 | $26 |
| Amiodarone | 28 | $483 | $17 |
| Lisinopril | 69 | $468 | $7 |
| Sotalol | 24 | $437 | $18 |
| Nitrostat | 24 | $418 | $17 |
| Amlodipine Besylate | 33 | $412 | $12 |
| Cartia Xt | 14 | $334 | $24 |
| Valsartan | 11 | $323 | $29 |
| Spironolactone | 30 | $304 | $10 |
| Digitek | 11 | $274 | $25 |
| Propafenone | 15 | $273 | $18 |
| Hydrochlorothiazide | 18 | $246 | $14 |
| Diltiazem 24hr Cd | 11 | $141 | $13 |
| Simvastatin | 12 | $122 | $10 |
| Metoprolol | 18 | $118 | $7 |
2014: 31 drugs
| Effient | 87 | $35,994 | $414 |
| Xarelto | 57 | $21,682 | $380 |
| Crestor | 21 | $10,631 | $506 |
| Pradaxa | 23 | $9,187 | $399 |
| Metoprolol | 92 | $3,866 | $42 |
| Ranexa | 13 | $3,461 | $266 |
| Pravastatin | 105 | $3,102 | $30 |
| Diovan | 15 | $2,702 | $180 |
| Bystolic | 16 | $2,285 | $143 |
| Potassium Chloride | 40 | $1,892 | $47 |
| Losartan | 80 | $1,282 | $16 |
| Atorvastatin | 52 | $1,201 | $23 |
| Digox | 26 | $1,112 | $43 |
| Carvedilol | 85 | $1,089 | $13 |
| Clopidogrel | 63 | $1,011 | $16 |
| Diltiazem 24hr Er | 36 | $1,001 | $28 |
| Digoxin | 23 | $948 | $41 |
| Flecainide Acetate | 40 | $924 | $23 |
| Isosorbide Mononitrate Er | 31 | $810 | $26 |
| Furosemide | 129 | $799 | $6 |
| Warfarin | 46 | $690 | $15 |
| Pantoprazole | 34 | $541 | $16 |
| Sotalol | 25 | $529 | $21 |
| Propafenone | 15 | $458 | $31 |
| Nitrostat | 32 | $441 | $14 |
| Lisinopril | 42 | $302 | $7 |
| Amlodipine Besylate | 24 | $227 | $9 |
| Fenofibrate | 11 | $202 | $18 |
| Spironolactone | 16 | $192 | $12 |
| Metoprolol | 19 | $149 | $8 |
| Benazepril | 11 | $101 | $9 |
2013: 25 drugs
| Effient | 53 | $22,969 | $433 |
| Xarelto | 35 | $13,338 | $381 |
| Crestor | 36 | $13,058 | $363 |
| Pradaxa | 14 | $7,750 | $554 |
| Diovan | 18 | $3,696 | $205 |
| Pravastatin | 129 | $2,727 | $21 |
| Metoprolol | 75 | $2,486 | $33 |
| Clopidogrel | 42 | $2,002 | $48 |
| Pantoprazole | 55 | $1,354 | $25 |
| Carvedilol | 89 | $1,328 | $15 |
| Atorvastatin | 30 | $1,296 | $43 |
| Diltiazem Er | 25 | $1,257 | $50 |
| Losartan | 47 | $856 | $18 |
| Potassium Chloride | 20 | $795 | $40 |
| Diltiazem 24hr Er | 26 | $658 | $25 |
| Isosorbide Mononitrate Er | 23 | $523 | $23 |
| Flecainide Acetate | 17 | $395 | $23 |
| Warfarin | 22 | $359 | $16 |
| Lisinopril | 44 | $350 | $8 |
| Furosemide | 58 | $296 | $5 |
| Metoprolol | 32 | $281 | $9 |
| Digox | 22 | $219 | $10 |
| Simvastatin | 19 | $160 | $8 |
| Amlodipine Besylate | 12 | $158 | $13 |
| Digoxin | 13 | $138 | $11 |
Money from drug and device companies
$1,321 in 2025
| 2025 | 11 | 33 | None | $1,321 |
| 2024 | 17 | 39 | None | $1,717 |
| 2023 | 17 | 55 | None | $3,070 |
| 2022 | 18 | 59 | $9,000 | $11,408 |
| 2021 | 14 | 86 | $36,000 | $38,096 |
| 2020 | 14 | 83 | $38,000 | $39,886 |
| 2019 | 18 | 113 | $32,450 | $36,763 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $308 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $307 | 6 payments
|
| Biotronik | Selectra | $223 | 2 payments
|
| Pfizer | Vyndaqel | $128 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $91 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $80 | 4 payments
|
See all 33 published payments
| Pfizer | Meals · 2025-12-19 | Vyndaqel | $17 |
| AGEPHA Pharma FZ | Meals · 2025-11-21 | Lodoco | $14 |
| Novartis Pharmaceuticals | Meals · 2025-11-14 | Leqvio | $17 |
| Pfizer | Meals · 2025-10-25 | Vyndaqel | $22 |
| Actelion Pharmaceuticals US | Meals · 2025-10-17 | Opsynvi | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-10 | Kerendia | $24 |
| Shockwave Medical | Meals · 2025-09-30 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $169 |
| Novartis Pharmaceuticals | Meals · 2025-09-19 | Leqvio | $17 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-13 | Adempas | $16 |
| Pfizer | Meals · 2025-08-29 | Eliquis | $25 |
| Shockwave Medical | Meals · 2025-08-27 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $139 |
| Amgen | Meals · 2025-08-15 | Repatha | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-08 | Eliquis | $20 |
| Pfizer | Meals · 2025-07-18 | Vyndaqel | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-28 | Kerendia | $23 |
| Biotronik | Meals · 2025-06-22 | Selectra | $73 |
| Actelion Pharmaceuticals US | Meals · 2025-06-20 | Opsumit | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-13 | Camzyos | $20 |
| Actelion Pharmaceuticals US | Education · 2025-05-26 | Opsumit | $79 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-16 | Adempas | $18 |
| Pfizer | Meals · 2025-05-12 | Vyndaqel | $24 |
| Amgen | Meals · 2025-05-09 | Repatha | $24 |
| Actelion Pharmaceuticals US | Meals · 2025-05-07 | Uptravi | $125 |
| Pfizer | Meals · 2025-05-02 | Eliquis | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-25 | Eliquis | $29 |
| Actelion Pharmaceuticals US | Meals · 2025-04-04 | Opsumit | $25 |
| Boston Scientific | Meals · 2025-03-15 | Watchman Flx | $28 |
| Esperion Therapeutics | Meals · 2025-03-07 | Nexletol | $14 |
| Amgen | Meals · 2025-02-28 | Repatha | $21 |
| Biotronik | Meals · 2025-02-04 | None | $150 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-31 | Camzyos | $21 |
| Novartis Pharmaceuticals | Meals · 2025-01-24 | Leqvio | $24 |
| Actelion Pharmaceuticals US | Meals · 2025-01-17 | Opsumit | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,717
| Abbott Laboratories | Optis | $742 | 8 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $202 | 5 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $199 | 1 payment
|
| Pfizer | Eliquis | $74 | 3 payments
|
| Amgen | Repatha | $71 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $68 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $54 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $50 | 2 payments
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $49 | 2 payments
|
| Kestra Medical Technology Services | Assure Wcd | $34 | 1 payment
|
| Esperion Therapeutics | Nexletol | $32 | 2 payments
|
| Penumbra | Penumbra System | $29 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $26 | 1 payment
|
| Medtronic | Micra | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Evkeeza | $22 | 1 payment
|
| Heartflow | Ffrct | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $19 | 1 payment
|
2023: $3,070
| Abbott Laboratories | Diamondback Coronary | $1,129 | 9 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $363 | 2 payments
|
| Biotronik | Biomonitor | $242 | 2 payments
|
| Inari Medical | Flowtriever Catheter, S | $218 | 2 payments
|
| Boston Scientific | Watchman Flx | $155 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $153 | 7 payments
|
| Acist Medical Systems | Hd-Ivus | $147 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Adempas | $138 | 3 payments
|
| Pfizer | Eliquis | $127 | 6 payments
|
| Amgen | Repatha | $94 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $82 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $79 | 6 payments
|
| Esperion Therapeutics | Nexletol | $42 | 2 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $35 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $26 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $18 | 1 payment
|
2022: $11,408
| Boston Scientific | Bg Mini Plus | $9,000 | 3 payments
|
| Cardiovascular Systems | Diamondback Coronary | $577 | 4 payments
|
| Actelion Pharmaceuticals US | Uptravi | $384 | 14 payments
|
| Biotronik | Biomonitor | $342 | 3 payments
|
| Shockwave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $242 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $198 | 5 payments
|
| Novartis Pharmaceuticals | Entresto | $120 | 9 payments
|
| Abiomed | Impella | $120 | 1 payment
|
| Inari Medical | Flowtriever Catheter, S | $112 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $54 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $53 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $51 | 4 payments
|
| Veryan Medical | Biomimics 3d Vascular Stent System | $42 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $40 | 2 payments
|
| Cardiva Medical | Cardiva Vascade 6/7f Vcs | $21 | 1 payment
|
| Pfizer | Eliquis | $21 | 1 payment
|
| Abbott Laboratories | Jot Dx | $19 | 1 payment
|
| Esperion Therapeutics | Nexletol | $12 | 1 payment
|
2021: $38,096
| Preventice Services | Bg Mini Plus | $36,000 | 12 payments
|
| Acist Medical Systems | Hd-Ivus | $489 | 4 payments
|
| Abbott Laboratories | Confirm Rx | $401 | 23 payments
|
| Biotronik | Rivacor | $336 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $153 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $147 | 8 payments
|
| Esperion Therapeutics | Nexletol | $121 | 4 payments
|
| Amgen | Repatha | $119 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $80 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $74 | 4 payments
|
| Amarin Pharma | Vascepa | $54 | 3 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $47 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $47 | 2 payments
|
| Philips Electronics North America | (8333) Igt D Coronary | $28 | 1 payment
|
2020: $39,886
| Preventice Services | None | $38,000 | 1 payment
|
| Abbott Laboratories | Xience Sierra Coronary Stent | $495 | 25 payments
|
| Medtronic Vascular | Heartware Hvad | $467 | 4 payments
|
| Amgen | Repatha | $171 | 6 payments
|
| Actelion Pharmaceuticals US | Opsumit | $150 | 6 payments
|
| Shockwave Medical | Vascular Lithotripsy | $131 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $103 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $89 | 10 payments
|
| Esperion Therapeutics | Nexletol | $64 | 3 payments
|
| Amarin Pharma | Vascepa | $62 | 3 payments
|
| Regeneron Healthcare Solutions | Praluent | $46 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $44 | 2 payments
|
| Biotronik | None | $43 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $21 | 1 payment
|
2019: $36,763
| Preventice Services | None | $30,000 | 1 payment
|
| Acist Medical Systems | Devices | $2,601 | 2 payments
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $770 | 9 payments
|
| Biotronik | None | $683 | 8 payments
|
| Medtronic Vascular | In.Pact Admiral | $567 | 9 payments
|
| Actelion Pharmaceuticals US | Opsumit | $406 | 17 payments
|
| Amgen | Repatha | $335 | 10 payments
|
| Janssen Pharmaceuticals | Xarelto | $332 | 16 payments
|
| Abbott Laboratories | Emboshield Nav6 System | $261 | 6 payments
|
| Portola Pharmaceuticals | Andexxa | $212 | 4 payments
|
| Regeneron Healthcare Solutions | Praluent | $178 | 9 payments
|
| Abiomed | Impella | $144 | 1 payment
|
| Terumo Medical | Optitorque | $100 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $80 | 4 payments
|
| Philips Electronics North America | Igt D Peripheral | $34 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $27 | 2 payments
|
| Gilead Sciences | Letairis | $20 | 1 payment
|
| InfoBionic | Mome Kardia | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1679666994
- Licence
- CA A56213California A56213: Current · expires 2028-07-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 2550 Samaritan Dr, Suite D, San Jose, CA, 95124
- NPI first listed
- 2006-09-30
- NPI last updated
- 2025-03-18
- NPI record certified
- 2025-03-18
This is when the NPI record was last certified, not a medical board exam.